Submitted August 16, 2004; accepted December 20, 2004 Purpose : To compare the efficacy and safety of u-hCG with r-hCG in IVF cycles. Methods : A prospective, investigator-blind, randomized, comparative study. Patients (n = 100) ≤35 years with IVF indication were randomly assigned on the day of hCG administration for oocyte maturation to receive either u-hCG (10,000 IU) or r-hCG (250 µg).
INTRODUCTION
It is well known that human chorionic gonadotropin (hCG) and luteinizing hormone (LH) have similar molecular structure and share 80% homology. Their capacity for binding to the same receptor was demonstrated more than 20 years ago (1) . hCG extracted from the urine of pregnant women has been widely used in both men and women undergoing infertility treatment with gonadotropins.
The recent availability of recombinant hCG (r-hCG; Ovidrel  , Serono Inc., São Paulo, Brazil), produced by transfecting non-human cell lines (Chinese hamster ovary cells) with human genetic material, has obviously raised interest in the possible benefits of this medication over conventional u-hCG for final oocyte maturation in IVF/ICSI (intracytoplasmic sperm injection) cycles. The removal of urinary contaminants increases both the purity and the local tolerability of hCG. hCG can induce oocyte maturation and ovulation through its ability to trigger germinal vesicle breakdown and extrusion of the first polar body and induce an increase in progesterone production (2) .
In limited, unpublished clinical studies, the halflife of r-hCG was estimated as ∼30 h (3). The efficacy of 250 µg r-hCG has been reported, and r-hCG has been shown to be well tolerated in the induction of final follicular maturation in women undergoing ART (4) . Additionally, a dose of 250 µg r-hCG appears to be clinically equivalent to 10,000 IU u-hCG in this group (4) .
A number of studies have compared r-hCG (250 µg) with a 5,000 IU dose of u-hCG. Driscoll et al., in a double-blind trial, found no statistically significant differences between intramuscular (i.m.) administration of u-hCG and subcutaneous (s.c.) administration of r-hCG in terms of the number of oocytes retrieved after stimulation with r-hFSH, meeting the predefined criteria for equivalence of the two drugs in ART (5) . By contrast, a multicenter study comparing 250 µg r-hCG with 5,000 IU u-hCG reported that a statistically higher mean number of mature oocytes was retrieved for the r-hCG group than for the u-hCG group (9.4 vs. 7.1, respectively; p = 0.027) (6) . This same study also reported significantly lower injection-site reactions for r-hCG, higher luteal progesterone levels and a trend to higher pregnancy and live birth rates in favor of r-hCG (33 vs. 25% and 27 vs. 23%, respectively). Finally, 250 µg r-hCG and 5,000 IU u-hCG have been shown to meet criteria for equivalence in women with group II anovulatory infertility who received hCG after follicular stimulation with rhFSH in a chronic low-dose protocol (7) . Again, local reactions to injection were significantly more common in patients treated with u-hCG.
The aim of the present study was to compare the efficacy of conventional u-hCG i.m. with r-hCG s.c. for inducing final oocyte maturation in IVF cycles, using a primary endpoint of mean number of retrieved oocytes.
MATERIALS AND METHODS
This prospective, blind, randomized comparative pilot study was conducted at Clínica e Centro de Pesquisa em Reprodução Humana Roger Abdelmassih, a private infertility center in São Paulo, Brazil.
Patients
One hundred patients ≤35 years of age and with indication for IVF were treated with a standard long GnRH agonist protocol of ovarian stimulation performed with r-hFSH (Gonal F  , Serono Inc., São Paulo, Brazil). Informed consent was obtained from all patients enrolled in the study the approval for which was given by the local Ethical Committee.
Treatment
Pituitary down-regulation was achieved after 14 days of s.c. leuprolide acetate (Reliser  , Serono Inc., São Paulo, Brazil), started on day 21 of the menstrual cycle (1 mg s.c. for 3 days followed by 0.5 mg daily up to day 5 of ovarian stimulation). r-hFSH (Gonal-f  , Serono Inc., São Paulo, Brazil) was administered with 300 IU/day after transvaginal ultrasonography revealed a thin endometrium and, on the same day, serum estradiol (E 2 ) concentrations were <40 pg/mL. After 5 days of stimulation, the GnRH agonist dosage was lowered to 0.25 mg/day. Ultrasound and E 2 monitoring were performed daily after 7 days of ovarian stimulation.
When at least two follicles of ≥18 mm mean diameter were detected, the GnRH agonist was discontinued and patients were randomly assigned to enter one of two groups: In the group receiving u-hCG, final oocyte maturation was induced with i.m. u-hCG (Profasi  10,000 IU, Serono Inc., São Paulo, Brazil), while in the group receiving r-hCG, final oocyte maturation was induced with s.c. r-hCG (Ovidrel  250 µg, Serono Inc., São Paulo, Brazil). Each patient was randomized blindly (using a computer-generated list) by a nurse on the day of hCG administration. The injection volume was 1.0 mL, the same for both hCG products. Patients self-administered the hCG injection. Prior to oocyte retrieval, a nurse interviewed the patient regarding injection site reactions attributed to the hCG injection.
For both groups, oocyte retrieval was carried out after a 34-36 h interval. Oocytes were denuded 1 h after retrieval with a Stripper Pipette  35 µm (Mid Atlantic Diagnostics Inc., Marlton, NJ, USA). Embryo transfer was performed 48-72 h later. Luteal phase support was started on the day of oocyte aspiration with vaginal progesterone, 90 mg twice a day (Crinone  , Serono Inc., São Paulo, Brazil). Physicians responsible for ovarian stimulation follow-up, oocyte retrieval, and embryo transfer, as well as biologists involved in laboratory procedures, were not aware of the group to which each patient belonged.
Assessment
The primary endpoint of the study was the mean number of oocytes retrieved. Secondary study endpoints included the number of oocytes retrieved, number of metaphase II (MII) oocytes, fertilization, implantation, pregnancy and miscarriage rates and injection site reactions. Statistical evaluation was performed using unpaired Student's t−test, Fisher's exact test and the Mann-Whitney test, as indicated. Only p values less than 0.05 were considered significant. As this was a pilot study, a power analysis and sample size calculation were not performed.
RESULTS
Patients from both groups were similar in terms of age, infertility factor, total dose of r-hFSH, E 2 levels on the day of hCG administration, and number of previous IVF attempts (Table I) . Comparison of the two groups showed no statistical difference in relation to total number of oocytes retrieved. The mean number of oocytes retrieved in the 10,000 IU u-hCG and 250 µg r-hCG groups was 17.3 and 15.6 oocytes/patient, respectively (p = 0.355). The percentage of MII oocytes was also similar between the two groups: 64.2 and 62.3% in patients treated with u-hCG and r-hCG, respectively (p = 0.442). As expected, therefore, the number of oocytes available for sperm injection was equivalent in both groups. A lack of statistical difference was also demonstrated in terms of fertilization rate (81.5 and 79.4% in the u-hCG and r-hCG groups, respectively; p = 0.514) and number of transferred embryos (3.0 and 3.2 embryos/patient for groups u-hCG and r-hCG, respectively; p = 0.466).
Although there seemed to be a trend to a higher frequency of positive beta hCG values and clinical pregnancy rate in the r-hCG group, the differences did not reach statistical significance. The percentage of patients with positive serum beta hCG levels (defined as ≥30 mIU/mL) 12 days after embryo transfer was 42.0% in patients treated with u-hCG and 58.3% in the r-hCG patients (p = 0.157). The percentages of clinical pregnancy, i.e. the presence of at least one gestational sac detected by transvaginal ultrasound scan, were 42.0 and 52.1% for the u-hCG and r-hCG groups, respectively (p = 0.418). Implantation rates also proved to be similar in both groups: 22.4% in the u-hCG group and 29.9% in the r-hCG group (p = 0.153). Patients were followed up to week 12 of gestation. Miscarriage rates in patients treated with u-hCG and r-hCG were also similar: 9.5 and 8.0%, respectively (p = 1.00). Finally, ongoing pregnancy rates did not reach statistical significance: 38.0 and 47.9% in the u-hCG and r-hCG groups, respectively (p = 0.414).
In terms of safety, adverse events were generally mild to moderate in severity. However, the incidence of adverse events in patients treated with u-hCG was significantly higher compared with the r-hCG group (45 vs. 23%, respectively; p = 0.0004). The vast majority of adverse events were injection-site reactions, occuring more frequently in the u-hCG group (38%) compared with the r-hCG group (13%) (p = 0.0001).
DISCUSSION
The importance of the mid-cycle LH surge for final oocyte maturation and ovulation is well established. The mid-cycle surge promotes follicular rupture (8), disruption of the oocyte-cumulus oophore cell contact and induction of the resumption of the oocyte's meiotic maturation phase (9), luteinization of granulosa cells (10) and secretion of progesterone.
As a consequence of its similarity with the LH molecule in terms of bioactivity, u-hCG has been widely used in assisted reproduction for inducing final follicular maturation and ovulation. We undertook this prospective, randomized study to compare the effects of 10,000 IU u-hCG with those of 250 µg r-hCG.
In this well-matched patient population, the two treatment groups, as expected, presented no difference in ovarian response, as assessed by the number of oocytes retrieved per patient and E 2 levels on the day of hCG administration. The percentage of MII oocytes retrieved was similar for both groups (Table I ). Similar fertilization rates suggest that the oocytes from both groups were comparable in terms of capacity for fertilization following the ICSI procedure.
Although statistical analysis did not reveal a significant difference for implantation, clinical pregnancy, and ongoing pregnancy rates, there seemed to be a slight improvement of such outcomes in the r-hCG group in comparison with the u-hCG group (29.9 vs. 22.4%, 42 vs. 52.1% and 38 vs. 47.9%, respectively). Despite the lack of statistical significance for these parameters in our pilot study, a trend to higher pregnancy rates and live birth rates after the use of r-hCG has also been reported elsewhere in a study comparing 250 µg r-hCG with 5,000 IU u-hCG (6) . While serum hCG and progesterone were not assessed in our study, concentrations of these hormones have been reported to be higher following administration of r-hCG compared with u-hCG (5,6). Similar to our findings, significantly better local tolerability has been reported with r-hCG (250 µg) compared with u-hCG (5,000 IU) (6) . It is well known that the non-hormonal proteins contained in urine-derived gonadotropin preparations are associated with severe local and systemic immunogenic reactions. In women who have suffered such reactions following injection of urine-derived gonadotropins, the administration of a recombinant product, such as r-hFSH, has been associated with improved tolerability and reduced immunogenicity (11, 12) . The improved tolerability of recombinant-derived products, including r-hCG, is a clear benefit in terms of patient acceptability and clinical outcome. An additional benefit for patients is the improved convenience of s.c. injection with r-hCG compared with i.m. injection of u-hCG.
In conclusion, therefore, our results indicate that 250 µg r-hCG is well tolerated and effective in inducing follicular maturation and early luteinization. Although the clinical outcomes in our study did not reach statistical significance, larger prospective and randomized studies will contribute to a better understanding of the possible benefits of r-hCG over conventional urinary preparations.
